Patient and graft survival of deceased donor transplant in one year’s post kidney transplant Experience of single center, what does need for results to be better than this?

A. Zomorrodi, Abulfazel Bohluli, F. Kakei, Mohsen Mohammadrahimi
{"title":"Patient and graft survival of deceased donor transplant in one year’s post kidney transplant Experience of single center, what does need for results to be better than this?","authors":"A. Zomorrodi, Abulfazel Bohluli, F. Kakei, Mohsen Mohammadrahimi","doi":"10.15761/nrd.1000152","DOIUrl":null,"url":null,"abstract":"Until this time the best modality for treatment of end stage renal failure (ESRD) is kidney transplantation, but the most important problem with that is shortage of donor. A deceased donor is the main provider of kidney and a relative and unrelative live donor is secondary provider of kidney for transplantation. But in deceased donor in comparing with live donor there is not a time for complete evaluation and almost to be in bad condition for deceased donor so it seems that there will be some difference in deceased and live donor outcome. We investigated patient and graft survival in deceased donor in one year after Transplantation in our center. Material and method: From 2003 until 2018 in our center there were 88 ESRD patients between age of 12 to 67 years 33 females 55males that have been transplanted with deceased donors , donors( between ages 5to 60 years 12 females 35 males) but we just only approached 85 cases of recipients (43 males and 42 females) and investigated for patient and graft survival : all of recipients have been treated with induction of ATG and then triple medicines Sandimune or Tacrolimuse and prednisolone and Imuran Cellcept and operation have been carried out with one team of surgery. Results: 8 cases expired about in first 2 months of operation (8 case in early times) and 77 patients were live in one year (90/58%) and overall 16-allograft loss in one year ,69 allografts survived in one year (81/17%). Conclusion: In our center one-year graft survival was 81/17% and patient survival was 90/58% which results may be comparable with other centers and it seems that the result can be better than this in our center which we will discuss in this paper. *Correspondence to: Afshar Zomorrodi, Professor of urology and kidney transplant surgeon, Head of organ transplantation Department, Imam Reza hospital, Tabriz medical science University, Tabriz -Iran, E-mail: dr_zomorrodi@ yahoo.com","PeriodicalId":160607,"journal":{"name":"Nephrology and Renal Diseases","volume":"45 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrology and Renal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/nrd.1000152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Until this time the best modality for treatment of end stage renal failure (ESRD) is kidney transplantation, but the most important problem with that is shortage of donor. A deceased donor is the main provider of kidney and a relative and unrelative live donor is secondary provider of kidney for transplantation. But in deceased donor in comparing with live donor there is not a time for complete evaluation and almost to be in bad condition for deceased donor so it seems that there will be some difference in deceased and live donor outcome. We investigated patient and graft survival in deceased donor in one year after Transplantation in our center. Material and method: From 2003 until 2018 in our center there were 88 ESRD patients between age of 12 to 67 years 33 females 55males that have been transplanted with deceased donors , donors( between ages 5to 60 years 12 females 35 males) but we just only approached 85 cases of recipients (43 males and 42 females) and investigated for patient and graft survival : all of recipients have been treated with induction of ATG and then triple medicines Sandimune or Tacrolimuse and prednisolone and Imuran Cellcept and operation have been carried out with one team of surgery. Results: 8 cases expired about in first 2 months of operation (8 case in early times) and 77 patients were live in one year (90/58%) and overall 16-allograft loss in one year ,69 allografts survived in one year (81/17%). Conclusion: In our center one-year graft survival was 81/17% and patient survival was 90/58% which results may be comparable with other centers and it seems that the result can be better than this in our center which we will discuss in this paper. *Correspondence to: Afshar Zomorrodi, Professor of urology and kidney transplant surgeon, Head of organ transplantation Department, Imam Reza hospital, Tabriz medical science University, Tabriz -Iran, E-mail: dr_zomorrodi@ yahoo.com
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
死亡供者移植后一年的患者和移植物存活率单中心经验,需要什么结果比这更好?
到目前为止,治疗终末期肾衰竭(ESRD)的最佳方式是肾移植,但最重要的问题是供体短缺。已故供者是肾脏的主要供者,亲属和非亲属活体供者是移植肾脏的次要供者。但是,与活体供体相比,死亡供体没有时间进行完整的评估,并且几乎处于不良状态,因此,死亡供体和活体供体的结果似乎存在一些差异。我们调查了在本中心死亡供体移植后一年内患者和移植物的存活情况。材料和方法:从2003年到2018年,我们中心有88例年龄在12至67岁之间的ESRD患者,33名女性55名男性,与已故供者移植,供者(年龄在5至60岁之间12名女性35名男性),但我们只接触了85例受体(43名男性和42名女性),并调查了患者和移植物的生存情况。所有受者均接受ATG诱导治疗,然后使用三联药物Sandimune或他克莫司、强的松龙和Imuran Cellcept,并由一组手术进行手术。结果:手术前2个月左右死亡8例(早期8例),1年内存活77例(90/58%),1年内共丢失16块同种异体移植物,1年内存活69块(81/17%)。结论:我中心移植术后1年生存率为81/17%,患者生存率为90/58%,与其他中心有一定的可比性,我中心的结果可能会更好,本文将对此进行讨论。*通讯:Afshar Zomorrodi,伊朗大不里士医科大学伊玛目礼萨医院泌尿科教授和肾移植外科医生,器官移植科主任,E-mail: dr_zomorrodi@ yahoo.com
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment Anti-glomerular basement membrane disease case series in Trinidad and Tobago Acute kidney injury (AKI): Risk assessment and management in hospital versus community Cyclosporine A nephrotoxicity: Downregulation of multidrug resistance associated protein 2 (MRP2) by upregulated miRNA133a Iatrogenic osteomalacia (case report). Seek advice from your nephrologist for bone and electrolyte disorders
wanfang
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1